Dec 5, 2011 · Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of ...
Dec 5, 2011 · The analysis was based on 3,797 BRCA1 mutation carriers and 2,392 BRCA2 mutation carriers diagnosed with invasive breast cancer. Median age at ...
Abstract. Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of.
Nov 2, 2011 · Germline mutations in BRCA1 and BRCA2 confer high risks of breast, ovarian and other cancers [1–3] and account for 15 to 20% of the excess ...
/ Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of Breast and Ovarian Cancers among BRCA1 and. BRCA2 Mutation Carriers: Results from the Consortium of. Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of breast and ovarian cancers among BRCA1 and. BRCA2 mutation carriers: results from the Consortium of. Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA).
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).